Biotech Calendar: 2011-12 FDA Drug Approvals
TheStreet.com
- Adcetris
- Affymax
- Alexion
- Alexza
- Alimera
- Alkermes
- Amlyin
- Antares
- Anturol
- AstraZeneca
- AZ-004
- Bio-T-Gel
- BioSante
- biotech
- Bristol-Myers Squibb
- Bydureon
- Corcept Therapeutics
- Corlux
- crizotinib
- Dapagliflozin
- Dendreon
- drug approvals
- Eli Lilly
- EXPAREL
- Eyelea
- FDA
- Iluvien
- Incyte
- Levadex
- MAP Pharmaceuticals
- Novartis
- NuPathe
- Pacira
- peginesatide
- Pfizer
- Provenge
- Regeneron
- Roche
- ruxolitinib
- Seattle Genetics
- Soliris
- Spectrum
- Takeda
- Teva Pharmaceuticals
- Zelboraf
- Zelrix
- Zevalin
Dendreon's Blowup Spreads Across Biotech
TheStreet.com
Biotech Calendar: Key Dates for August
TheStreet.com
5 Healthcare Companies With August Catalysts
Seeking Alpha
Regeneron Pharmaceuticals Earnings Preview
Motley Fool
The 15 Most-Watched BioPharma Stocks
Motley Fool
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Yahoo
Regeneron's VENICE Study to Continue
Yahoo/Zacks